Group 1: Performance and Sales Strategy - The company is optimizing sales channels and product pricing, which has temporarily impacted Q4 2024 and Q1 2025 performance [2] - The optimization and pricing restructuring is a dynamic and ongoing process, with specific measures varying by market feedback [2] - The company aims to complete clinical trials for its recombinant type III humanized collagen freeze-dried fibers this year [2][3] Group 2: Product Development and Innovation - The company has established a joint laboratory with France's Sentein Laboratory to enhance R&D capabilities, focusing on raw material development and technical cooperation [3] - In 2025, the company has launched five new products, including sunscreen and facial masks, with more products expected to be released [3] Group 3: Production Capacity and Future Plans - The company currently has production lines for class III medical devices and is considering capacity expansion if sales are substantial post-launch [3] - The R&D team is expected to continue growing in both expertise and size [3] Group 4: Financial Strategy - The 2024 dividend plan includes cash dividends and capital reserve transfers to increase stock liquidity and enhance market performance [3]
敷尔佳(301371) - 2025年4月24日投资者关系活动记录表